The Drugreporter Podcast

Psychedelic research in the Czech Republic has a long and distinguished history. At ICPR 2026, we spoke with psychiatrist and neuroscientist Tomáš Páleníček about clinical research, altered states of consciousness...

At ICPR 2024, we talked to Wim van den Brink, MD, PhD, Professor of Psychiatry and Addiction at the Academic Medical Center, University of Amsterdam, about the potential of psychedelics to reduce compulsive thinking and...

What actually makes psychedelic therapy work? Is it the drug, the therapeutic setting, or the human relationship between therapist and participant? At ICPR 2026, we spoke with psychiatrist and researcher Sandeep Nayak...

At ICPR 2024, we talked to anthropologist and author Nicolas Langlitz about the current hype around psychedelics, their place in medicine and culture, and why he sees them as holding the promise of moksha in the age of...

Women make up more than half of the population, yet they remain significantly underrepresented in psychedelic research. At ICPR 2026, we spoke with neuroscientist Grace Blest-Hopley about the gender gap in psychedelic...

At ICPR 2024, we talked to psychologist and psychotherapist Marc B. Aixalà about how so-called “bad trips” can be reframed as difficult but potentially transformative experiences, and the importance of integration in...

Tadeusz Hawrot is the founder of the Psychedelic Access and Research European Alliance (PAREA), a Brussels-based initiative working to prepare Europe for the integration of psychedelic-assisted therapies into healthcare...

With the new EU drug strategy now adopted, key questions remain about its direction and implementation—especially the balance between public health, human rights, and security. We spoke with Anna Dovbakh, Chair of the...

As Hungary heads toward a pivotal election, the camera turns on two of its most prominent drug policy advocates. In this interview conducted by Arild Knutsen, Drugreporter founders Péter Sárosi and István Gábor Takács...

The global drug control system is under growing pressure, as countries experiment with regulation and long-standing assumptions are being challenged. Martin Jelsma, who is stepping down from the Transnational Institute...

Ten years after the 2016 UN General Assembly Special Session on drugs (UNGASS), a new report by the International Drug Policy Consortium takes stock of progress and remaining gaps in global drug policy. We spoke with...

After 15 years at the helm of the International Drug Policy Consortium, Ann Fordham is stepping down as Executive Director. Under her leadership, IDPC has grown into one of the most influential global networks...

Jeremy Rudy, founder of the Sabba Collective, explains how psychedelic therapy can be integrated into society safely and responsibly — from education to policy. Jeremy Rudy is the founder and CEO of the Sabba...

Pavel Bém is a Czech psychiatrist and former mayor of Prague who now serves as National Drug Policy Coordinator. With decades of experience at the intersection of politics and addiction medicine, he has been a key...

Senator Jeff Steinborn is the sponsor of the Medical Psilocybin Act in New Mexico, a visionary step toward expanding access to psychedelic therapy. In this conversation, filmed at the Psychedelic Science 2025 conference...